Black TNBC Patients Lack Equitable Access to PARP Inhibitors, Flatiron Health Real-World Study Shows
Black patients were less likely to receive PARP inhibitors, despite having BRCA1/2 testing and positivity rates comparable to White patients, and were at higher risk of death.
The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) ...
November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod ...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS ...
One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for ...
Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...
Merck & Co., Inc. (NYSE: MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection ...
This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback